Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

BACKGROUND: Entecavir (ETV) is recommended as a first-line anti-HBV treatment. However, many chronic hepatitis B patients initiate anti-HBV treatment such as lamivudine and telbivudine with low genetic barriers in China, which leads to compensatory mutations and increases the rate of ETV resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Jin, Zhou, Juan, Liu, Huan, Ise, Rili M., Tu, You, Ran, Jinqiu, Bai, Lang, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420064/
https://www.ncbi.nlm.nih.gov/pubmed/34488678
http://dx.doi.org/10.1186/s12879-021-06554-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420064/
https://www.ncbi.nlm.nih.gov/pubmed/34488678
http://dx.doi.org/10.1186/s12879-021-06554-1

Ejemplares similares